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Mutations in the p53 gene are the most common genetic alter-
ations in human cancers, including solid tumours such as colon
and lung carcinomas (Soussi et al, 2000). The p53 tumour
suppressor gene is located on chromosome 17p13 and encodes a
nuclear 393-amino acid nuclear transcription factor which is
implicated in the regulation of normal cell growth and apoptosis
(Levine, 1997). Most of the known p53 gene alterations are
missense mutations clustered in the evolutionarily highly
conserved exons 4–8 (Soussi et al, 2000). These mutations result
in a biologically inactive p53 protein that stably accumulates in the
cell nucleus and can be detected by immunohistochemistry. In the
absence of wild-type p53 protein, genetic aberrations are more
likely to accumulate, leading to genetic instability and cell trans-
formation. 
It has been demonstrated that p53 mutations can lead to the
production of p53-Ab which can be detected in the sera of patients
with various types of cancers (Soussi, 2000). These antibodies
recognize immunodominant epitopes localized in the amino-and,
to a lesser extent, in the carboxy-terminus of human p53 (Lubin
et al, 1993; Schlichtholz et al, 1994; Vennegoor et al, 1997).
Antibodies specific for the central region are always poorly abun-
dant or absent (Lubin et al, 1993). These findings are totally in
accordance with the work performed in mice on the production of
p53 monoclonal antibodies (mAbs). Immunization of mice with
either murine, xenopus or human wild-type p53 led to the produc-
tion of mAbs directed to linear epitopes localized in the amino-and
carboxy-terminus of p53 (Vojtesek et al, 1992; Bartek et al, 1993;
Legros et al, 1994a; Hardy-Bessard et al, 1998). MAbs specific for
the central region of the protein were obtained only after a special
immunization or selection procedure (Legros et al, 1994b;
Vojtesek et al, 1995). 
Taken together, i) the presence of immunodominant epitopes
outside the hot spot region for p53 mutations, ii) the correlation
between p53 accumulation (and p53 gene mutation) in tumour
cells and p53-Ab responses, iii) the similarity of humoral
responses in patients independent of the cancer type, and iv) the
similarity of antigenic site profiles in patients and hyperimmun-
ized animals, all suggest that p53 accumulation is the major
component of the humoral response in patients with cancer. This
accumulation could lead to a self-immunization process culmin-
ating in the appearance of p53-Abs. As stated above, the level of
p53 proteins in a normal organism is very low, suggesting very
weak (if any) tolerance to endogenous p53. Isotyping of p53-Abs
has shown that they correspond mainly to IgG1 and IgG2
subclasses, while some patients exhibit a predominant IgA
response (Lubin et al, 1995). Some patients also had IgM,
although none had p53 IgM as the only isotype. No IgG3 or IgG4
was detected. Again, this result strengthens the hypothesis of an
active humoral response to p53. 
Recently, two genes referred to as p63 and p73, have been
found to encode proteins that share significant amino acid identity
in the transactivation domain (30%), the DNA binding domain
(60%) and the oligomerization domain (37%) with p53 (Marin
and Kaelin, 2000). This homology suggests that the products of
this gene family may act as transcription factors but their biological
functions are likely to be distinct. There is little evidence for p73
and p63 mutations in human cancer, but several consistent reports
indicate that the p73 protein accumulates in the nucleus of tumour
cells from different types of cancer (Ikawa et al, 1999). In our
effort to study the immune response toward the p53 protein, the
discovery of these new p53-related proteins raised several import-
ant questions. Do p53-Abs cross-react with p73, p63 or both? If
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is the basis for the immune response. Furthermore, the observa-
tion that p73 is accumulated in various types of cancer suggest
that it could be the target for an immune response in cancer
patients. 
MATERIALS AND METHODS 
Patients 
148 sera from patients with various types of cancer and 50 sera
from healthy controls were tested for p63 and p73 antibodies.
The distribution of cancer was as followed: 26 patients with
head and neck cancer (HNC), 104 with lung cancer (LC), 17
with breast cancer (BC), one with bladder cancer. All these
patients were previously tested for p53-Abs by ELISA (Lubin
et al, 1995; Zalcman et al, 1998). Sera were obtained after diag-
nosis, but prior to any treatment. 7 ml of whole blood was
centrifuged at 3000 r.p.m. for 15 min and supernatant stored at 
–80˚C until use. 
ELISA and immunoprecipitation procedures 
All sera were previously tested for p53-Ab by the ELISA proced-
ure (Lubin et al, 1995). p73 and p63 antibodies were screened by
immunoprecipitation using S35-labelled proteins obtained by in
vitro transcription-translation using the T7 TNT-coupled reticulo-
cyte lysate (Promega); 20 000 cpm of p53, p73 or p63 was mixed
with 1 µ l of serum in a final volume of 200 µ l of RIPA buffer
(10 mM Tris hydrochloride, pH 8.0, 150 mM NaCl, 1 mM EDTA,
1% NP40, 0.5% sodium deoxycholic acid). After 2 h of incubation
on ice, 20 µ l of protein A sepharose was added and the reaction
was left for 20 min at 4˚C with gentle shaking. After 3 washes with
1 ml of RIPA buffer, bound proteins were eluted with Laemmli
buffer and analysed by SDS-PAGE. Normal serum from a blood
bank donor previously tested by ELISA and immunoblotting
served as a negative control. 
p53 was expressed from the construct BH11 which contains the
full-length wild-type p53 cloned in Bluescribe (Stratagene) (Ory
et al, 1994). p73 protein was expressed from pCMVp73 which
contains the full-length wild-type p73α (Kaghad et al, 1997). p63
protein was expressed from a construct that contains only the
∆ Np63γ form of p63 (Trink et al, 1998). Although it was originally
named p40, we will name it p63 in order to adhere to the common
nomenclature used for the p53 gene family (Levrero et al, 2000).
D Caput and D Sidransky generously provided p73 and p63
constructs respectively. 
Mapping of p53, p73 and p63 epitopes 
Using PCR, various regions of the cDNA encoding for p53, p63
and p70 were amplified (see delimitation of the region in Figure 1).
In each case, the 5′ primer contained a T7 promoter followed by
an ATG codon in frame with the coding region that was ampli-
fied. After amplification, the PCR product was directly used for
in vitro transcription and translation as described above. This
procedure was previously used for the epitope mapping of
various p53 monoclonal antibodies (Legros et al, 1993). 
RESULTS 
p53, p73 and p63 cross reactivity 
Homology between these three proteins is mainly localized to the
central DNA binding domain (Figure 1A). Homology in the
amino-terminus is restricted to the mdm2 binding site whereas the
homology in the carboxy-terminus is localized in the oligomeriza-
tion domain. We have produced several panels of mAbs toward
human and xenopus p53 (Legros et al, 1994a; Hardy-Bessard et al,
1998). About 60% of these mAbs recognized an immunodominant
epitope localized in the amino-terminus of the p53 that contains
the binding site of p53 to mdm2 (Figure 1B). Surprisingly, none of
the p53 mAbs directed toward either human or xenopus p53 cross-
react with either p73 or p63 (data not shown). Furthermore, a
rabbit serum raised toward the amino-terminus of p73 shows no
cross-reaction toward the p53 protein (data not shown). These
results suggest that the immunogenicity of these three proteins
could be different. 
p73 and p63 antibodies in the sera of cancer patients 
148 sera from cancer patients were tested for the presence of p73
and p63 antibodies (Table 1). 72 sera were previously demon-
strated to contain p53 antibodies, whereas 76 were negative (see
Materials and Methods). For the pre-screening procedure, equal
amounts of labelled p73 and p63 were mixed and proceeded for
immunoprecipitation with sera as described in Material and
Methods. This procedure led to the detection of 22 sera reacting
with p73 and 4 with p63 (Table 1). Then, each positive serum was
tested separately by immunoprecipitation with p53, p73 and p63.
As shown in Figure 2 and Table 1, there are clearly 4 types of sera
depending on the protein recognized. Three sera were positive for
the 3 proteins, 8 sera were positive for p73 and p53, 10 sera were
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Figure 1 (A) Schematic representation of the structure of p53, p73 and
p63. N: amino-terminus with the transactivation domain (absent in this form
of p63); M: central region with the core DNA binding domain; C: region with
the oligomerization domain for the 3 proteins and the carboxy-terminus of
p53 and p63: X; SAM domain which is specific for p73a. (B) Sequence
comparison of the amino-terminus of p53, p63 and p73. This region contains
the immunodominant epitopes of the p53 protein. The box delineates the
mdm2 binding site of p53 with key residues indicated by an asterisk.
Underlined sequence of p73 corresponds to the peptide used for
immunizationpositive for p73 and 1 serum was positive for p73 and p63. As
shown in Figure 2, immunoprecipitation of p73 or p63 led to a
strong signal, suggesting that the level of serum antibodies is high.
Indeed, dilution experiments have shown that sera diluted to 1/50
lead to a clear positive signal (data not shown). The detection of
p73-Abs in p53-negative sera suggests that this is a true immune
response toward p73. This is strengthened by the observation that
the frequency of p73-Abs is similar in the p53 positive and nega-
tive populations. Nevertheless, we cannot exclude that there are
some antibodies that could react with the two proteins. 
Epitope mapping of p53, p73 and p63 antibodies 
We have previously demonstrated that the p53 protein contains
immunodominant epitopes localized in the amino-, and to a lesser
extent, in the carboxy-terminus of the protein. Monoclonal or
polyclonal p53-Abs are generally directed toward theses epitopes,
whether from mice or humans. Using truncated protein, we have
mapped the region of p73 and p63 reacting with serum antibodies.
The same procedure was also applied to the p53 protein. Results
are shown in Figures 3–5 and are summarized in Tables 2–4. p53-
Abs reacted mainly with the N and C fragment, confirming our
previous mapping experiments using either short peptides or
Circulating p73 antibodies in cancer patients 59
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Figure 2 Immunoprecipitation of in vitro translated p53, p63 and p73 with sera from patients and healthy donor. In vitro translated proteins were
immunoprecipitated with each serum as described in Materials and Methods. X4 to X8: serum from blood donor; HNC: serum from patient with head and neck
cancer; LC: sera from patients with lung cancer 
Table 1 Frequency of p73 and p63 antibodies in sera with and without p53 antibodies 
Number of sera p53-Abs p73-Abs p63-Absa
Head and neck (HNC) 26 26 2 2 
Lung (LC) 28 28 6 1 
Breast (BC) 17 17 3 0 
Bladder (UC) 1 1 0 0 
All p53-positiveb 72 72 11 (15.3%) 3 (4.2%) 
p53 Negative (lung only)c 76 0 11 (14.5%)  1 (1.3%) 
Healthy controls 50 0 2 0 
aAll sera reacting with p63 also recognized p73. bAll these sera were previously shown to have p53-Abs
by ELISA. Most of them were also tested by immunoprecipitation in the present studies, confirming the
presence of p53-Abs. cAll these sera were previously shown to be devoid of p53-Abs by ELISA. Sera
with p73-Abs were checked for p53-Abs by immunoprecipitation and were found to be negative. 
Table 2 Epitope mapping of p53 antibodies in sera devoid of p73 and p63
antibodies (8 patients) 
Serum p53 IP p53 Epitope mapping p73 IP p63 IP 
NM C  
HNC191 + ––+ ––
HNC136 + + – + ––
HNC250 + + – + ––
HNC255 + + – + ––
LC846 + + – + ––
LC991 + + – + ––
LC365 + ––+ ––
LC329 + ––+ ––
IP: presence (+) or absence (–) of antibodies tested by immunoprecipitation.
Regions N, M and C are defined in Figure 1. Western blot with truncated protein (Figures 3 and 4). Some sera
also contained p53-Abs that reacted with the central region of the
protein (M fragment) (Figure 4 and Table 4). 
Strikingly, the behaviour of p73-Abs was totally different. All
sera with p73-Abs reacted with the M fragment that contains the
central DNA binding region (Figures 3–5 and Tables 3 and 4).
5 sera reacted also with the C fragment that contains the
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Figure 3 Epitope mapping of serum from patient LC1040. Various regions of
the p53 and the p73 protein were amplified by PCR and translated in vitro as
described in Materials and Methods (see Figure 1 for the delineation of the
various regions). In: Input corresponding to the various labelled proteins used
for immunoprecipitation. For p73, input was loaded in two lanes (ln and ln′ ) as
several products had a similar apparent molecular weight. F: full-length
protein 
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Figure 4 Epitope mapping of serum from patient HNC293. Various regions
of the p53, p63 and the p73 protein were amplified by PCR and translated in
vitro as described in Materials and Methods (see Figure 1 for the delineation
of the various regions). Arrowheads indicate the migration of the various
proteins. F: full-length protein 
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Figure 5 Epitope mapping of 4 sera on p73 protein. Various regions of the
p73 protein were amplified by PCR and translated in vitro as described in
Materials and Methods (see Figure 1 for the delineation of the various
regions). In: Input corresponding to the various labelled proteins used for
immunoprecipitation. They were loaded in two lanes (ln and ln′ ) as several
products have a similar apparent molecular weight. F: full length protein 
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Figure 6 Follow-up of patients DEB and MOU. Labelled p73 and p53 was
immunoprecipitated as described in Materials and Methods. (–) negative
control; (+) positive control. For patient DEB, lanes 1 to 6 corresponds to
days 1, 26, 54, 111, 139 and 232 after diagnosis. For patient MOU, lanes 1 to
4 corresponds to days 1, 128, 288 and 383 after diagnosis. The second band
below p53 corresponds to a truncated p53 produced during in vitro
translation 
Table 3 Epitope mapping of p73 and p63 antibodies in sera devoid of p53 antibodies (11 patients) 
Serum p73 IP p73 Epitope mapping p63 IP p63 Epitope mapping p53 IP 
NMCX N M C  
LC265 + – ++– + – + ––
LC207 + – ++–– –
LC215 + – + –– – –
LC220 + – ++–– –
LC247 + – + –– – –
LC256 + – ++–– –
LC266 + – + – + ––
LC281 + – + – + ––
LC286 + – + –– – –
LC306 + – + – + ––
LC330 + – + –– – –
IP: presence (+) or absence (–) of antibodies tested by immunoprecipitation. Regions N, M, C and X are defined in Figure 1. oligomerization domain and 3 with the carboxy-terminus that
contains the SAM domain (Tables 3 and 4). No serum contained
antibodies specific for the N fragment that contains the amino-
terminus of p73. A similar result was obtained with sera
containing p63-Abs, as these 4 sera interacted only with the M
fragment of p63, with no antibodies toward the N and the C frag-
ment. Sera from 4 patients (LC 238, LC 311, LC1040 and LC277),
contained a high level of antibodies directed toward the M frag-
ment of p73 that did not cross-react with the same region of p53
despite extensive homology (Figure 3 and Table 4). 
p73 antibodies and follow-up 
It has previously been shown that p53-Abs can be used for moni-
toring the follow-up of patients during therapy (Hammel et al,
1997; Polge et al, 1998; Zalcman et al, 1998). The presence of
p73-Abs was tested in a series of patients for whom serum was
available during therapy (data not shown, patients diffrent from
those described in Table 1). Two patients were found to have p73-
Abs. One patient (DEB) had p53-Abs and the other was negative
(MOU). Patient DEB had a small cell lung cancer (SCLC) and
underwent a complete response to therapy (chemotherapy
followed by radiotherapy) (Zalcman et al, 1998). Patient DEB was
shown to have a decrease in p53-Abs during the therapy demon-
strated by ELISA and which was confirmed in the present study by
immunoprecipitation (Figure 6) (Zalcman et al, 1998). A similar
observation was made for p73-Abs (Figure 6). Patient MOU had
no p53-Abs but displayed a strong response to p73 that seemed to
be constant. This patient was apparently free of cancer but
displayed mycobacterium Kansasii pulmonary infection. 
DISCUSSION 
p53-Abs in the sera of patients with breast cancer were first
detected in 1982 (Crawford et al, 1982). Subsequent studies
demonstrated that these antibodies are found in the sera of patients
with different types of cancer but are absent in the normal popula-
tion (Soussi, 2000). These antibodies are usually associated with
the accumulation of mutant p53 protein in the tumour. Recently
discovered p53 family proteins, such as p73 and p63, were shown
to have significant amino acid homology and share some functions
with the p53 protein. Although the eventual implication of p73 in
human cancer is not fully elucidated, it is essential to evaluate the
specificity of the p53 humoral response toward these two new p53
homologues. 
p73-Abs were found in 14.9% of the 148 sera from cancer
patient and in 4% of the 50 healthy control (P = 0.03, χ 2 test). 
The present study focused primarily on lung and head and neck
patients with tumours associated with a p53 immune response. It
would be of interest to test other cancer populations in order to
gain a more precise evaluation of p73-Ab frequency, especially in
tumours that are not associated with p53-Abs such as melanoma
and brain tumours. 
One of our main interests was to determine whether p53-Abs
found in sera of cancer patients could cross-react with p73 or p63.
The positive rate for anti-p73 antibody was similar in sera with
p53-Abs and those without p53-Abs, suggesting that the p73
protein can also induce a humoral response in cancer patients. 
For further characterization of these autoimmune antibodies,
epitope mapping was performed using protein fragments of p53,
p73 and p63. As previously shown (Lubin et al, 1993), epitopes for
anti-p53 Abs are mainly located in the amino- and carboxyl-
terminus of p53, whereas the majority of anti-p73 antibodies recog-
nize the central part of the p73 protein. All p73-Abs react with the
central region of p73, whereas none recognize the amino-terminus
of the protein. This observation is in striking opposition with the
situation observed for p53. Indeed, 4 sera (LC 238, LC 311,
LC1040 and LC277), react with the central region of p73 without
any cross-reaction with the central region of p53. Taken together,
these results confirm the specificity of p53-Abs toward the p53
protein as none of the p73-Abs react with the immunodominant
epitope of p53. Furthermore, we report for the first time that the
p73 protein can elicit a specific immune response in cancer
patients. 
The frequency of p63 Abs is low compared to p53 or p73. They
have been found only in patients with p73-Abs. Thus, it is difficult
to determine whether these antibodies arise from a specific
immune response toward p63 or if there is a cross-reaction of
between the two proteins which share 80% homology in the
central region. A recent report has described a unique syndrome in
which patients had chronic ulcerative stomatosis associated with
antibodies toward a 70-kDa nuclear protein (Lee et al, 1999).
Cloning and sequencing the cDNA coding for this protein reveal
it to be the human p63 suggesting that p63 could also be
Circulating p73 antibodies in cancer patients 61
British Journal of Cancer (2001) 84(1), 57–63 © 2001 Cancer Research Campaign
Table 4 Epitope mapping of p73 and p63 antibodies in sera with p53 antibodies (11 patients) 
Serum p53 IP p53 Epitope mapping p73 IP p73 Epitope mapping p63 IP p63 Epitope mapping 
NM C N M  C X NM C  
HNC240 + + + + + – + –– + – + – 
HNC293 + + + + + – + –– + – + – 
LC238 + + – ++ – + –– + – + – 
LC311 + + – ++ – ++ a –  – 
LC243 + + + + + – + –– –  
LC1040 + + – ++ – + –– –  
LC277 + –– ++ – + –– –  
LC437 + + + + + – + –– –
BC 15 + – ++ + – + –– –  
BC 28 + ND ND ND + ND  ND ND ND – 
UC 338 + ND ND ND + ND  ND ND ND – 
IP: presence (+) or absence (–) of antibodies tested by immunoprecipitation. ND: Not determined (no sample remained for epitope mapping). Regions N, M, C
and X are defined in Figure 1. a Weak positivity.immunogenic, but there are no data indicating whether these anti-
bodies also cross-react with p73 (Lee et al, 1999). 
The status of p73 in human cancer is still a matter of debate.
Although LOH of the p73 gene is high in several types of cancer,
there is no definitive proof that the remaining p73 allele is inacti-
vated. p73 mutations seem to be a very rare event. However, the
expression of p73 has been shown to be higher in tumour tissue
than in the corresponding normal tissue both at the mRNA level
(Loiseau et al, 1999; Takada et al, 1999; Yokomizo et al, 1999) and
at the protein level (Bjork-Eriksson et al, 1999; MacCallum and
Hupp, 1999; Peters et al, 1999; Scherr, 1999; Tannapfel et al, 1999;
Cai et al, 2000; Herath et al, 2000; Ng et al, 2000). The origin of
such increased expression and its function in tumorigenesis is not
known, but it could be involved in the triggering of this p73
immune response. Only studies combining a parallel evaluation of
p73 expression and p73-Abs could elucidate this phenomenon. 
Immunodominant epitopes in the p53 protein are localized
predominantly in the amino-terminus of the protein. Fine mapping
indicates that region 16 to 30 is highly immunogenic with 3
residues essential for antibody recognition, (residues 19, 23, 26),
regardless of whether they are mAbs raised in mouse or p53-Abs
from patient sera (Portefaix et al, 2000). These 3 residues have
been shown to be essential for the binding of mdm2 to p53,
suggesting that this region of p53 is highly accessible and local-
ized at the surface of the protein (Kussie et al, 1996). Indeed,
mAbs specific for this region compete with mdm2 for p53 binding.
This region is conserved between p53 and p73, and it has been
shown that mdm2 binds to p73 both in vitro and in vivo. This
binding does not lead to the degradation of p73 and it is not known
whether the recognition has any biological significance, or
whether it occurs under physiological conditions. The observation
that none of the sera with p73-Abs recognize this region despite
sequence and biological homology suggests that its accessibility is
different, and its biological function could be different as well. 
The observation that all p73-Abs recognize the central region of
the p73 protein raises several questions concerning its structural
and spatial organization. The central region of the p53 protein is
poorly immunogenic and only special immunization and screening
procedures have permitted obtaining monoclonal antibodies
directed to this domain. It has been suggested that such a
hydrophobic region is very compact in the native p53 protein and
buried inside the whole tetramer. One class of mutation found in
human cancer changes the conformation of the protein, revealing
several hidden epitopes (Legros et al, 1994b; Ory et al, 1994).
Although the sequence homology between the central region of
p53 and p73 is about 60%, the 2 regions behave differently. This is
supported by the observation that SV40 large T antigen binds only
to p53 through this central region, whereas p73 does not recognize
the viral protein (Marin et al, 1998). 
The present work confirms the specificity of p53-Abs found in
the sera of patients with different types of cancer. The finding of
specific p73-Abs unrelated to the presence of p53-Abs indicates
that the status of p73 in human cancer deserves to be more care-
fully analysed. 
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